The effects of guanethidine, bretylium and debrisoquine on the accumulation of noradrenaline in constricted postganglionic sympathetic nerves in vitro.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D002415:Cats; D003647:Debrisoquin / Q000494:pharmacology; D005725:Ganglia, Autonomic / Q000378:metabolism; D006145:Guanethidine / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology*; D008026:Ligation; D008854:Microscopy, Electron; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D009411:Nerve Endings / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism*; D013997:Time Factors
D000959:Antihypertensive Agents; D001949:Bretylium Compounds; D007546:Isoquinolines; D008996:Monoamine Oxidase Inhibitors; D003647:Debrisoquin; D009638:Norepinephrine; D006145:Guanethidine